SKYLA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2013.
Drug data last refreshed 11h ago · AI intelligence enriched 14h ago
SKYLA is a subdermal intrauterine levonorgestrel-releasing system approved in 2013 for contraception. It releases a synthetic progestin directly into the uterus to prevent pregnancy through multiple mechanisms including cervical mucus thickening and endometrial suppression. SKYLA is a small-molecule hormone delivery device positioned as a lower-dose alternative to other levonorgestrel IUDs.
SKYLA is in peak lifecycle but faces significant intra-Bayer cannibalization; limited growth trajectory suggests smaller, specialized commercial team focus.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on SKYLA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on SKYLA offers exposure to women's health and contraceptive markets with stable, regulated customer bases (OB/GYN providers, pharmacies). However, the brand's peak lifecycle stage and approaching LOE limit growth opportunities and team expansion; career value lies in execution excellence and market defense rather than innovation or scaling.